Llwytho...
New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Research focused on barriers to the real‐world use of CDK4/6 inhibitor therapy in patients with HR+/HER2– breast cancer reveals potential mechanisms and biomarkers of drug resistance.
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncologist |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons, Inc.
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262301/ https://ncbi.nlm.nih.gov/pubmed/34181796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13875 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|